Canopy Growth buys German medical cannabis company for $343M

The Canadian Press
May 02, 2019
By The Canadian Press
SMITHS FALLS, Ont. - Canopy Growth Corp. has signed a deal to buy a German company that specializes in cannabinoid-based medical therapies used by European physicians for roughly $342.9 million.

Under the deal, the Ontario-based company has acquired C3 Cannabinoid Compound Co.

C3's main medicinal offering is dronabinol, a compound with standardized concentrations of THC (tetrahydrocannabinol), the main psychoactive compound in cannabis.

Dronabinol is available in Austria, Denmark and Germany.

C3 has two manufacturing facilities specializing, respectively, in natural extraction and synthetic cannabinoid production.

The company's senior management team is expected to continue with the business.
Grow Opportunity
GET CONNECTED

Stay in-the-know on innovative ways to manage your cannabis business, and grow better. Subscribe to our weekly eNewsletter and be the first to hear what’s new in this fast growing industry.

Add comment


Security code
Refresh

Subscription Centre

 
New Subscription
 
Already a Subscriber
 
Customer Service
 
View Digital Magazine Renew

Most Popular

Latest Events

MJBizConNEXT
Wed Jun 12, 2019
Grower Day
Tue Jun 18, 2019
Cannabis Career Festival
Fri Sep 27, 2019

We are using cookies to give you the best experience on our website. By continuing to use the site, you agree to the use of cookies. To find out more, read our Privacy Policy.